Gut Oxygen Therapy for Ischemic-Hypoxic Bowel Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Oxygen (O2) -Sham group, Sham -Oxygen (O2) group.
- Who it may be relevant to
- Registry conditions: Chronic Ischemic-Hypoxic Enteropathy. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Efficacy and Safety of Gut Oxygen Therapy for Ischemic-Hypoxic Bowel Disease: A Single-center, Double-blind, Randomized, Intra-individual Crossover Controlled Study
Overview
This single-center, double-blind, randomized, intra-individual crossover controlled study aims to investigate the efficacy and safety of intestinal oxygen therapy via a deep intestinal catheter as a targeted route for intestinal oxygen delivery in the treatment of ischemic-hypoxic enteropathy, and simultaneously to explore and verify the chronobiological differences. Data have been obtained from the study based on the first version of our pilot study. Considering ethics and cost-effectiveness, a new protocol needs to be designed to achieve the research goals with minimal intervention, minimal cost, and the smallest sample size.
Detailed description
Eligible subjects meeting all inclusion criteria and none of the exclusion criteria will be randomized in a crossover manner within the individual to receive, via a deep intestinal catheter, either 500 mL of oxygen or placebo (sham group), administered at three separate time points over the course of one day. The data of test results before and after treatment were collected to evaluate the efficacy and safety of gut oxygen therapy.
Interventions
- Other Oxygen (O2) -Sham group
Subjects will receive interventions in a crossover manner at three separate time points over one day as follows: Time 1: 500 mL of oxygen (flow rate: 1 L/min) Time 2: 500 mL of no air (no oxygen) Time 3: 500 mL of oxygen (flow rate: 1 L/min) - Other Sham -Oxygen (O2) group
Subjects will receive interventions in a crossover manner at three separate time points over one day as follows: Time 1: 500 mL of no air (no oxygen) Time 2: 500 mL of oxygen (flow rate: 1 L/min) Time 3: 500 mL of oxygen (flow rate: 1 L/min)
Primary outcome measures
- Changes in arterial blood gas [Time frame: Perioperative/Periprocedural]
Secondary outcome measures (5)
- Changes in electrocardiographic data [Time frame: Perioperative/Periprocedural]
- Changes in electroencephalographic data [Time frame: Perioperative/Periprocedural]
- Overall patient satisfaction with intervention. [Time frame: Perioperative/Periprocedural]
- The incidence rate of adverse events [Time frame: Perioperative/Periprocedural]
- The changes in gut microbiota composition and metabolites before and after treatment. [Time frame: Perioperative/Periprocedural]
Eligibility criteria
Inclusion criteria
- Definite diagnosis of chronic heart failure or obstructive sleep apnea (OSA) with chronic hypoxia;
- Comorbid intestinal dysmotility (abdominal distension, constipation, diarrhea, or abdominal pain);
- Disease duration ≥1 month with poor response to conventional treatment;
- Tolerability of transendoscopic enteral tubing (TET) with successful placement of the tube at the ileocecal junction;
- Age 18-80 years;
- Able to cooperate with bed rest therapy and provide written informed consent.
Exclusion criteria
- Oxygenation index >400 without supplemental oxygen and/or resting oxygen saturation ≥96%;
- Primary organic gastrointestinal diseases, intestinal obstruction, inflammatory bowel disease, or severe hepatic/renal failure;
- Hemodynamically unstable, unable to tolerate sequential intervention (time-sequenced intervention);
- Presence of cough or spinal disorders that prevent maintaining a resting state during bed rest;
- Failure of arterial catheterization or endoscopic tube placement;
- Mental or cognitive impairment that precludes cooperation with assessments.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple blind
- Primary purpose
- Treatment
Study locations
China · 1 center
- The Second Affiliated Hospital of Nanjing Medical University — Nanjing
Publications
- Chen A, Teng C, Wei J, Wu X, Zhang H, Chen P, Cai D, Qian H, Zhu H, Zheng X, Chen X. Gut microbial dysbiosis exacerbates long-term cognitive impairments by promoting intestinal dysfunction and neuroinflammation following neonatal hypoxia-ischemia. Gut Microbes. 2025 Dec;17(1):2471015. doi: 10.1080/19490976.2025.2471015. Epub 2025 Feb 26. PMID 40008452
- Van Welden S, Selfridge AC, Hindryckx P. Intestinal hypoxia and hypoxia-induced signalling as therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017 Oct;14(10):596-611. doi: 10.1038/nrgastro.2017.101. Epub 2017 Aug 30. PMID 28853446
- Dvornikova KA, Platonova ON, Bystrova EY. Hypoxia and Intestinal Inflammation: Common Molecular Mechanisms and Signaling Pathways. Int J Mol Sci. 2023 Jan 26;24(3):2425. doi: 10.3390/ijms24032425. PMID 36768744
Identifiers
NCT: NCT07621367 · GOT-RCT